key: cord-1042785-knx70ukf authors: Li, Hongxin; Zhao, Yong; Zhou, Lin; Hu, Jin title: Cutaneous, skin histopathological manifestations and relationship to COVID‐19 infection patients date: 2020-08-08 journal: Dermatol Ther DOI: 10.1111/dth.14157 sha: 0be06618ea5755cabb121b009de99cee9b934abb doc_id: 1042785 cord_uid: knx70ukf BACKGROUND: COVID‐19 diseases have been a nationwide pandemic condition. However, cutaneous, skin histopathological manifestations of COVID‐19 infection are not well described. Our study aims are to present heterogeneous cutaneous, histopathological manifestations in COVID‐19 patients, to investigate the possible relationship between cutaneous manifestations and histopathological features in COVID‐19 infection. MATERIALS AND METHODS: We performed a systemic review in PubMed database and Chinese medical journal search engines which were wangfang.data (http://www.wanfangdata.com.cn/), Science China (http://www.cnki.net/) until June 17(th), 2020. Search terms “COVID‐19”, “SARS‐Coronavirus‐2” and “Coronavirus” were used in combination with “cutaneous”, “rash”, “skin”, “dermatology”. RESULTS: 75 papers were included with confirmed COVID‐19 infection. The most frequent cutaneous manifestation of COVID‐19 present was erythema, nearly 38.4%. Trunk was the most affected location, presenting in 51.4% patients. Rash occurred before onset of other symptoms was in 5.3% patients. 77 patients were received treatments. Rash was dismissed in 49% patients, improved in 21.2% patients ranged from 0‐17 days. The histopathological examination present in 39 patients. CONCLUSION: Skin is one of target organs affected by COVID‐19 infection. Cutaneous manifestations should be paid more attention. It can help doctors diagnose COVID‐19 infection in prodromal stage, understand progression, and determine prognosis of COVID‐19 infection. This article is protected by copyright. All rights reserved. Coronavirus is a big family which can The mortality is high in patients over 65 years with comorbidities, such as diabetes, This article is protected by copyright. All rights reserved. hypertension, cardiovascular involvements, or cancer. The frequent symptoms at onset are fever, cough, fatigue, anosmia, myalgia, dyspnea, acute respiratory distress syndrome (ARDS), sputum production, headache, haemoptysis, diarrhoea. (7) (8) (9) COVID-19 can damage multi-systems, such as respiratory system, central nervous system, gastrointestinal tract, hematological system, cardiovascular system, urinary system, skin. Cutaneous manifestations are heterogeneous. Some patients presented with more than one kind of cutaneous lesions. ( Table 2 ). On March 11th, 2020, World Health Organization declared COVID-19 was a pandemic viral infection. Rightnow, the confirmed cases were more than 8 million globally by June 17th. COVID-19 attacks alveolar epithelial cells through angiotensin-converting enzyme 2 (ACE2) which is ACE of isozyme, as well as cellular receptor for COVID-19, mainly found in cardiovascular, kidney, testes, lung, colon, and other organizations. (11) ACE2 plays an important role in incising Ang II to generate Ang1-7, which antagonizes Ang II-induced vascular smooth muscle contraction, cell proliferation, exudation of neutrophils, macrophages and fibrinous, vascular inflammation, loss of pulmonary ventilation function and trouble of maintaining oxygenation. (12, 13) Interleukin (IL)-6 is one of main pro-inflammatory factors resulting in cytokine storm, enhancing vascular permeability, weakening organ function. Elevation of IL-6 level was found in severe, critically ill COVID-19 patients, as a biomarker for severity assessment. (14) This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. occasional necrotic keratinocytes, perivascular infiltration of lymphocytes and eosinophils, dermal edema. (21) In our study, we only found two patients had sequelae of hyperpigment on onset day 10, and 21 respectively. If the sequelae can disappear needs time to tell. Treatments of CI are combination of anti-viral medicine (hydroxychloroquine, lopinavir/ritonavir) and antibiotics (azithromycin, levofloxacin, ceftriaxone The Coronavirus Disease 2019 (COVID-19) Pandemic Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding A Novel Coronavirus from Patients with Pneumonia in China The novel zoonotic COVID-19 pandemic: An expected global health concern The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome Chilblains are a common cutaneous finding during the COVID-19 pandemic: a retrospective nationwide study from France A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients C-reactive protein, obesity, and the risk of arterial and venous thrombosis COVID-19: consider cytokine storm syndromes and immunosuppression Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis Acro-ischemia in hospitalized COVID-19 patients Cutaneous manifestations in COVID-19: a first perspective SARS-CoV-2 infection presenting as a febrile rash Comment on: Cutaneous manifestations in COVID-19: a first perspective. Safety concerns of clinical images and skin biopsies Cutaneous manifestations in COVID-19: the experiences of Barcelona and Rome A dermatologic manifestation of COVID-19: Transient livedo reticularis Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak Cutaneous manifestations in patients with COVID-19: A preliminary review of an emerging issue Cutaneous hyperesthesia: A novel manifestation of COVID-19 Vesicles Shed by Pathological Murine Adipocytes Spread Pathology: Characterization and Functional Role of Insulin Resistant/Hypertrophied Adiposomes Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases Cutaneous Signs in COVID-19 Patients: A Review A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19 infection Histologic features of long lasting chilblain-like lesions in a pediatric COVID-19 patient Skin manifestations of COVID-19 Cutaneous small-vessel vasculitis associated with novel 2019 coronavirus SARS-CoV-2 infection (COVID-19) Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms Comment on 'Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East': pernio unrelated to COVID-19 Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia The authors have indicated they have no competing interests.